Диссертация (1139881), страница 16
Текст из файла (страница 16)
Reynolds HR, Srichai MB, Iqbal SN et al. Mechanisms ofmyocardial infarction in women without angiographically obstructive coronaryartery disease // Circulation, 2011, No. 124, pp. 1414–1425.122148. Ribeiro DD, Lijfering WM, Rosendaal FR, Cannegieter SC. Risk ofvenous thrombosis in persons with increased body mass index and interactionswith other genetic and acquired risk factors // J Thromb Haemost, 2016, Vol. 14,No. 8, pp. 1572-8.149.
Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC,Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in womenover 50 years old using oral contraception or postmenopausal hormone therapy //J Thromb Haemost, 2013, Vol. 11, No. 1, pp. 124-31.150. Roach RE, Lijfering WM, Rosendaal FR, Cannegieter SC, le CessieS. Sex difference in risk of second but not of first venous thrombosis: paradoxexplained // Circulation, 2014, Vol. 129, No. 1, pp. 51-6.151. Rosenberg D, Eichorn A, Alarcon M, et al. External validation of therisk assessment model of the International Medical Prevention Registry onVenous Thromboembolism (IMPROVE) for medical patients in a tertiary healthsystem // J Am Heart Assoc, 2014, No.
3, P. e001152.152. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis // JThromb Haemost, 2009, No. 7 Suppl 1, pp. 301-4.153. Rosendaal FR, VAN Hylckama Vlieg A, Doggen CJ. Venousthrombosis in the elderly // J Thromb Haemost, 2007, No. 5 Suppl 1, pp. 310-7.154. Rosendaal FR. Causes of venous thrombosis // Thromb J, 2016, No.14(Suppl 1), P.
24.155. Rosendaal FR. Venous thrombosis: a multicausal disease // Lancet,Vol. 353, 1999, No. 9159, pp. 1167-73.156. Rosendaal FR. Национальный конгресс с международнымучастием. Тромбозы, гемостаз и патология сосудов: осовремененныеподходы к диагностике и лечению // Thrombophilia testing. Москва. 2014.157. Rossetto V, Barbar S, Vedovetto V, et al. Physicians' compliancewith the Padua Prediction Score for preventing venous thromboembolism amonghospitalized medical patients // J Thromb Haemost, 2013, No. 11, pp. 1428-30.123158. Rossi E, Ciminello A, Za T, Betti S, Leone G, De Stefano V.
Infamilies with inherited thrombophilia the risk of venous thromboembolism isdependent on the clinical phenotype of the proband // Thromb Haemost, 2011,Vol. 106, No. 4, pp. 646-54.159. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for theWomen’s Health Initiative Investigators. Risks and benefits of estrogen plusprogestin in healthy postmenopausal women: principal results From the Women’sHealth Initiative randomized controlled trial // JAMA, 2002, No. 288, pp. 321–333.160. Samad F, Ruf W.
Inflammation, obesity, and thrombosis // Blood,2013, Vol. 122, No. 20, pp. 3415-22.161. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demandtype 2 myocardial infarction // J Am Coll Cardiol, 2014, No. 63, pp. 2079–2087.162. Sandsmark DK, Messé SR, Zhang X, et al; CRIC StudyInvestigators. Proteinuria, but not eGFR, predicts stroke risk in chronic kidneydisease: Chronic Renal Insufficiency Cohort Study // Stroke, 2015, No.
46, pp.2075–2080.163. Schellong SM. Importance of thrombophilia screening // Internist(Berl), 2014, Vol. 55, No. 5, pp. 529-30.164. Seguí R, Estellés A, Mira Y, España F, Villa P, Falcó C, Vayá A,Grancha S, Ferrando F, Aznar J. PAI-1 promoter 4G/5G genotype as anadditional risk factor for venous thrombosis in subjects with geneticthrombophilic defects // Br J Haematol, 2000, Vol. 111, No. 1, pp. 122-8.165. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE.Maternal and paternal history of myocardial infarction and risk of cardiovasculardisease in men and women // Circulation, 2001, No.
104, pp. 393–398.166. Shah RS, Cole JW. Smoking and stroke: the more you smoke themore you stroke // Expert Rev Cardiovasc Ther, 2010, No. 8, pp. 917–932.124167. Silverstein MD, Heit JA, Mohr DN et al. Trends in the incidence ofdeep vein thrombosis and pulmonary embolism: a 25-year populationbased study// Arch Intern Med, 1998, No.
158, pp. 585-593.168. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormonetherapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study(HERS) // Circulation, 2001, No. 103, pp. 638–642.169. Singh GM, Danaei G, Farzadfar F, et al; Global Burden of MetabolicRisk Factors of Chronic Diseases Collaborating Group; Asia-Pacific CohortStudies Collaboration (APCSC); Diabetes Epidemiology. The age-specificquantitative effects of metabolic risk factors on cardiovascular diseases anddiabetes: a pooled analysis // PLoS One, 2013, No.
8, P. e65174.170. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G,Gore JM, Goldberg RJ. Incidence rates, clinical profile, and outcomes of patientswith venous thromboembolism. The Worcester VTE study // J ThrombThrombolysis, 2009, No. 28, pp. 401-409.171. Spyropoulos AC, Anderson FA Jr, FitzGerald G.
Predictive andassociative models to identify hospitalized medical patients at risk for VTE //Chest, 2011, Vol. 140, No. 3, pp. 706-714.172. Spyropoulos AC, McGinn T, Khorana AA. The use of weighted andscored risk assessment models for venous thromboembolism // Thromb Haemost,2012, No. 108, pp. 1072–1076.173. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A,Helmerhorst FM, Stijnen T, Dekkers OM.
Different combined oral contraceptivesand the risk of venous thrombosis: systematic review and network meta-analysis// BMJ, 2013, No. 347, P. f5298.174. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment modelsfor venous thromboembolism in acutely ill medical patients. A systematic review// Thromb Haemost, 2017, Vol. 117, No. 4, pp. 801-808.175. Tasdemir S, Erdem HB, Sahin I, Ozel L, Ozdemir G, Eroz R, TatarA. Correlation with Platelet Parameters and Genetic Markers of Thrombophilia125Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI1, β-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in IschemicStrokes // Neuromolecular Med, 2016, Vol.
18, No. 2, pp. 170-6.176. The 2004 United States Surgeon General’s Report: The HealthConsequences of Smoking // N S W Public Health Bull, 2004, No. 15, P. 107.177. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, WhiteHD, Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for theUniversal Definition of Myocardial Infarction, et al. ESC Committee for PracticeGuidelines (CPG). Third universal definition of myocardial infarction // EurHeart J, 2012, No.
33, pp. 2551–2567.178. Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections andinflammatory diseases as risk factors for venous thrombosis. A systematic review// Thromb Haemost, 2012, No. 107, pp. 827–837.179. TimpJF,BraekkanSK,VersteegHH,CannegieterSC.Epidemiology of cancer-associated venous thrombosis // Blood, 2013, No. 122,pp. 1712–1723.180. Tirschwell DL, Smith NL, Heckbert SR, et al.
Association ofcholesterol with stroke risk varies in stroke subtypes and patient subgroups //Neurology, 2004, No. 63, pp. 1868–1875.181. Tormene D, Ferri V, Carraro S, Simioni P. Gender and the risk ofvenous thromboembolism // Semin Thromb Hemost, 2011, No. 37, pp. 193-198.182. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O,Laraudogoitia E, et al. A meta-analysis of individual data regarding prevalenceand risk markers for myocarditis and infarction determined by cardiac magneticresonance imaging in myocardial infarction with non-obstructive coronary arterydisease // Atherosclerosis, 2015, No.
241, pp. 87–91.183. Van De Craen B, Declerck PJ, Gils A. The Biochemistry, Physiologyand Pathological roles of PAI-1 and the requirements // Thromb Res, 2012, Vol.130, No. 4, pp. 576-85.126184. Van De Water NS, French JK, Lund M, Hyde TA, White HD,Browett PJ. Prevalence of factor v Leiden and prothrombin variant g20210a inpatients age <50 years with no significant stenoses at angiography three to fourweeks after myocardial infarction // Journal of the American College ofCardiology, 2000, Vol. 36 No 2, pp 717–722185. Vilahur G, Ben-Aicha S, Badimon L. New insights into the role ofadipose tissue in thrombosis // Cardiovascular Research, 2017, Vol.
113, No. 9,pp. 1046–1054.186. Violi F, Cangemi R, Calvieri C. Pneumonia, thrombosis and vasculardisease // J Thromb Haemost, 2014, Vol. 12, No. 9, pp. 1391-400.187. Walker ID , Greaves M , Preston FE. Investigation and managementof heritable thrombophilia // British Journal of Haematology, 2001, No. 114, pp.512 - 528.188. Wang TJ, Massaro JM, Levy D, et al.
A risk score for predictingstroke or death in individuals with new-onset atrial fibrillation in the community:the Framingham Heart Study // JAMA, 2003, No. 290, pp. 1049–1056.189. Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH,Cheng WJ, Nie B, Ge HL, Jia DA, Yang SW, Yan ZX. Obesity andcardiovascular thrombotic events in patients undergoing percutaneous coronaryintervention with drug-eluting stents // Heart, 2009, Vol. 95, No. 19, pp. 1587-92.190. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al; WHIInvestigators.
Effect of estrogen plus progestin on stroke in postmenopausalwomen: the Women’s Health Initiative: a randomized trial // JAMA, 2003, No.289, pp. 2673–2684.191. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M; BritishCommittee for Standards in Haematology. Guideline on aspects of cancer-relatedvenous thrombosis // Br J Haematol, 2015, Vol. 170, No.
5, pp. 640-8.192. Wattanakit K, Lutsey PL, Bell EJ, et al. Association betweencardiovascular disease risk factors and occurrence of venous thromboembolism: atime-dependent analysis // Thromb Haemost, 2012, No. 108, pp. 508–515.127193. Wen CP W.X. Stressing harms of physical inactivity to promoteexercise // Lancet, 2012, No.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
